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Introduction 
It is recommended that the model questionnaire on drug use among prisoners should be introduced with an 
explanation of the aim and objectives of the study, how the results will be used, and a description of the survey’s 
guiding principles, especially with regard to privacy and confidentiality. The introduction should be adjusted according 
to the preferred method used to administer the questionnaire (e.g. computer-assisted personal interview (CAPI), 
face-to-face interview, self-administered questionnaire, etc.), to the national language of the prisoner and to her/his 
educational level (REITOX NFPs, 2013). The methodological specifications annexed to the current questionnaire 
describe the principles and the guidelines for the survey. 
 
The aim of the questionnaire is to create a basic module of a core set of questions, based on questions already used 
by several countries in prison. However not all possible questions are included in the European questionnaire and 
single countries or prisons can add the questions they consider most appropriated and useful at national or local 
level.    
 
(A) General information 
 
A.1 Date of interview (YYYY/MM/DD) 
/_______/____/____/ 
 
A.2 Sex 
1. male 
2. female 
8. not stated/refused  
9. not known 
Methodological specifications 
Basic epidemiological information. In face-to-face interview the interviewer will check the answer without asking the question. 
 
A.3 Age (in years)  
/________/ 
Methodological specifications 
Age at the time of the survey. 
 
A.4 What is your nationality? 
1. national of this country 
2. national of another country (specify__________) 
3. other (specify________) 
8. not stated/refused 
9. not known 
comments/specifications ___________ 
Methodological specifications 
If it is not permissible by law to record nationality, this should be specified in the methodological comments at the end of the 
questionnaire. 
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A.5 What is your country of birth? 
Country: __________________________ 
Methodological specifications 
If it is not possible to answer questions A.4 and/or A.5 on nationality, please specify what the reasons are and describe them in the 
methodological comments at the end of the questionnaire.  
 
A.6 What is your legal status? 
1. untried detainee  
2. sentenced prisoner who has appealed  
3. detainee who has not yet received a final sentence, but has started serving their custodial sentence in advance 
4. sentenced prisoner  
5. other case (specify_____) 
8. not stated/refused 
9. not known 
 
Methodological specifications 
Categories are taken from ‘Table 4: Legal status of prison populations on 1st of September 2011’, from SPACE 1 (Aebi and Del 
Grande, 2011). The categories used in the SPACE report are: 
1. Untried: a court decision has not been reached yet. 
2. Prisoners who have appealed or who are within the statutory limit for doing so. 
3. Detainees who have not received a final sentence yet, but who have started serving a prison sentence in advance. 
4. Prisoners with a final sentence; among this group are persons detained for fine conversion reasons (fine defaulters) and 
persons detained because of the revocation, suspension or annulment of the conditional release or probation. 
In cases where the categories are not applicable to the legislation and regulations of a country, please specify this in the 
methodological specifications for this question. 
 
A.7 How long have you been in prison for the current period of imprisonment? 
1. less than six months 
2. six months to less than one year 
3. one year to five years 
4. more than five years 
8. not stated/refused  
9. not known 
Methodological specifications 
This refers to the current period of imprisonment. 
 
A.8 How many times have you been in prison, excluding your current improsonment? 
1. never 
2. one time 
3. two to five times 
4. more than five times 
8. not stated/refused 
9. not known 
Methodological specifications 
This refers to the number of times the person was in prison prior to this occasion, regardless of her/his legal status. 
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(B) Drug use outside and inside prison 
B.1 Drug use outside prison 
It is recommended that this section should be introduced with an explanation of the objective of the survey, and how 
the information will be used. It is important to be clear about the reference time and place where the drug use took 
place, for every part of the section.  
 
B.1.1 Outside prison, before your current imprisonment, have you ever used any of the following 
drugs, even if just once? 
Substance groups 
 
 
Specific substances 
 
B.1.1.1 
Ever used drug(s) outside 
prison before current 
imprisonment 
1. yes 
2. no  
8. not stated/refused 
9. not known 
B.1.1.2 
Used drug(s) during the last 12 
months outside prison before 
current imprisonment 
1. yes 
2. no 
8. not stated/refused 
9. not known 
B.1.1.3 
Used drug(s) during the last 30 
days outside prison before 
current imprisonment 
1. yes 
2. no 
8. not stated/refused 
9. not known 
Tobacco     
Alcohol     
Cannabis     
Cocaine 
 
   
Powder cocaine HCl    
Crack cocaine    
 Others (specify)    
Stimulants other than 
cocaine 
 
   
Amphetamines    
Methamphetamines    
Ecstasy    
 Others (specify)    
Hallucinogens 
 
   
Hallucinogenic mushrooms     
Ketamine    
 LSD     
 Others (specify)    
Opioids 
 
   
Heroin     
Methadone misused (1)    
Buprenorphine misused (1)    
Fentanyl illicit/misused (1)    
 Other opioids (specify)    
Hypnotics/sedatives 
 
   
Barbiturates misused (1)    
Benzodiazepines misused (1)    
GHB/GBL    
Other hypnotics/sedatives 
misused (1) 
   
Volatile inhalants/solvents     
New substances imitating 
the effect of illicit drugs 
such as cannabis, cocaine, 
etc. 
Specify which substances 
are imitated 
   
Anabolic steroids     
Other substances (specify)     
     
Not known     
Methodological specifications 
The substances are based on the list provided in the Handbook for surveys on drug use among the general population (EMCDDA, 
2002) and the Treatment demand indicator (TDI): standard protocol 3.0 (EMCDDA, 2012a). Countries should adapt this list of 
substances to their national language and should also include the street names for drugs that are used in that country. The question 
should also be adapted to the method used for the interview. ‘Substance use’ means illicit drug use, with the exception of alcohol 
                                                          
(1) Without a doctor’s prescription. 
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and tobacco. If no information is available on the specific subtype of drug, the broader category of the drugs can be used. A logical 
sequence of questioning should be followed, and some questions may be skipped — if the inmate has never used any drug in their 
lifetime the section should be skipped and the questionnaire should continue at section ‘(D) Health status’. In cases where the broad 
category of drugs is used, please specify which sub-categories of drugs are included in the broad category. 
 
B.1.2 (Answer this question only if you have ever used drugs, and responded YES to question B1.1.1 for one or more of the listed 
drugs. Otherwise, go to section B.2.) If your answer to B1.1.2 or B1.1.3 is YES, then logically your answer to B1.1.1 should be YES 
too. 
 
How old were you (in years) when you first used these drugs?  
 
Substance groups 
 
 
Specific substances 
 
B.1.2.1 
Age at first use of every drug 
(indicate the age in years: /____/) 
Tobacco   
Alcohol   
Cannabis   
Cocaine 
 
 
Powder cocaine HCl  
Crack cocaine  
 Others (specify)  
Stimulants other than cocaine 
 
 
Amphetamines  
Methamphetamines  
Ecstasy  
 Others (specify)  
Hallucinogens 
 
 
Hallucinogenic mushrooms   
Ketamine  
LSD   
 Others (specify)  
Opioids 
 
 
Heroin   
Methadone misused (2)  
 Buprenorphine misused (1)  
 Fentanyl illicit/misused (1)  
 Other opioids (specify)  
Hypnotics/sedatives 
 
 
Barbiturates misused (2)  
Benzodiazepines misused (2)  
 GHB/GBL  
 Other hypnotics/sedatives misused (2)  
New substances imitating the effect of illicit 
drugs such as cannabis, cocaine, etc. 
Specify which substances are imitated  
Volatile inhalants/solvents   
Anabolic steroids   
Other substances (specify)   
   
Not known   
 
Methodological specifications 
See methodological specifications on drug use from question B.1.1. 
Indicate the age in years for all drugs you have ever used, even if you have only used them once.
                                                          
(2) Without a doctor’s prescription. 
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B.1.3 (Answer this question only if you have been in prison (for your current imprisonment) for less than one year (question A7=1 
or A7=2) AND you answered YES to one or more of the listed drugs listed in B1.1.3. Otherwise, go to question B.2.)  
 
How often did you use drugs outside prison in the last 30 days before your current 
imprisonment? 
 
Substance groups 
 
Specific substances 
 
1. 1–3 days in 
the last 30 days 
 
2. 4–9 days in 
the last 30 
days 
3. 10–19 days 
in the last 30 
days 
4. 20 days or 
more in the 
last 30 days  
8. not stated/ 
refused 9. not known 10. not used 
Tobacco         
Alcohol         
Cannabis         
Cocaine 
 
       
 Powder cocaine HCl        
 Crack cocaine        
 Others (specify)        
Stimulants other than cocaine  
 
       
 Amphetamines        
 Methamphetamines        
 Ecstasy        
 Others (specify)        
Hallucinogens 
 
       
 Hallucinogenic mushrooms         
 Ketamine        
 LSD         
 Others (specify)        
Opioids 
 
       
 Heroin         
 Methadone misused (3)        
 Buprenorphine misused (3)        
 Fentanyl illicit/misused (3)        
 Other opioids (specify)        
Hypnotics/Sedatives  
 
       
 Barbiturates misused (3)        
 Benzodiazepines misused (3)        
 GHB/GBL        
 Other hypnotics/sedatives 
misused (3) 
       
Volatile inhalants/solvents         
New substances imitating the 
effect of illicit drugs such as 
cannabis, cocaine, etc. 
Specify which substances 
are imitated 
       
Anabolic steroids         
Other substances (specify)         
         
Not known         
 
Methodological specifications 
See methodological specifications on drug use for questions B.1.1 and B.1.2. 
A logical sequence of questioning should be followed, and some questions may be skipped — if the inmate has never used any 
drug in their lifetime the section should be skipped and the questionnaire should continue at section ‘(D) Health status’. In cases 
where the broad category of drugs is used, please specify which sub-categories of drugs are included in the broad category. 
                                                          
(3) Without a doctor’s prescription. 
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B.2 Drug use inside prison  
It is recommended that an introduction should be provided to this section, making clear the reference time for the questions. The 
question asks about experience with drug use in the lifetime of the prisoners within the prison premises, either during the current 
imprisonment or during a previous imprisonment, either in her/his own country or abroad. The question asks whether respondents 
have ever used drugs in any prison (B.2.1.1), and during their current imprisonment (B.2.1.2). If the respondent has used drugs 
inside prison in the current imprisonment, it asks if the drug use occurred in the last 12 months or the last 30 days) (B.2.1.3 and 
B.2.1.4).  
 
B.2.1 During the time you have been in prison during your current imprisonment and/or during a 
previous imprisonment (in your own country or abroad), have you ever used any of the following 
drugs, even if just once? 
 
Substance groups 
 
Specific substances 
 
B.2.1.1 
Ever used in any prison 
1. yes 
2. no 
8. not stated/refused 
9. not known 
B.2.1.2 
Ever used in the 
current imprisonment
1. yes 
2. no  
8. not stated/refused 
9. not known 
B.2.1.3 
Used during the last 12 
months in the current 
imprisonment  
1. yes 
2. no 
8. not stated/refused 
9. not known 
B.2.1.4 
Used during the last 30 
days in the current 
imprisonment  
1. yes 
2. no  
8. not stated/refused 
9. not known 
Tobacco      
Alcohol      
Cannabis      
Cocaine Powder cocaine HCl     
 
 Crack cocaine     
 Others (specify)     
Stimulants other than 
cocaine  
Amphetamines     
 
 Methamphetamines     
 Ecstasy     
 Others (specify)     
Hallucinogens 
 
    
 Hallucinogenic mushrooms      
 Ketamine     
 LSD      
 Others (specify)     
Opioids 
 
    
 Heroin      
 Methadone misused (4)     
 Buprenorphine misused (4)     
 Fentanyl illicit/misused (4)     
 Other opioids (specify)     
Hypnotics/sedatives  
 
    
 Barbiturates misused (4)     
Benzodiazepines misused (4)     
GHB/GBL     
Other hypnotics/sedatives 
misused (4) 
    
New substances imitating 
the effect of illicit drugs 
such as cannabis, 
cocaine, etc. 
Specify which substances 
are imitated 
    
Volatile 
inhalants/solvents 
     
Anabolic steroids      
Other substances 
(specify) 
     
      
Not known      
Methodological specifications 
See methodological specifications on drug use from previous questions. A logical sequence of questioning should be followed, and 
some questions may be skipped — if the prisoner has never used any drug inside prison this section should be omitted and the 
questionnaire should continue at section ‘(C) Drug injecting and other health risk behaviours’. The answers to questions B.2.1.3 and 
                                                          
(4) Without doctor’s prescription 
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B.2.1.4 are not applicable (NA) if a prisoner has been in prison during the current imprisonment for less than 12 months (answers 1 
or 2 to question A.7) or less than 30 days (answer 1 to question A.7). In cases where the broad category of drugs is used, please 
specify which sub-categories of drugs are included in the broad category. 
 
B.2.2 (Answer this question only if you have ever used drugs inside prison during the current imprisonment or in another prison, 
whether in your own country or abroad, and have responded YES to B.2.1.1 and/or B.2.1.2.). Otherwise go to section C 
Did you first use these drugs while you were inside prison (‘inside prison’ means both your 
current and any previous imprisonment)?  
Substance groups 
 
Specific substances 
 
B.2.2.1 
First use inside prison (during current or 
previous imprisonment) 
1. yes 
2. no 
8. not stated/refused 
9. not known 
Tobacco   
Alcohol   
Cannabis   
Cocaine 
 
 
 Powder cocaine HCl  
 Crack cocaine  
 Others (specify)  
Stimulants other than cocaine  
 
 
 Amphetamines  
 Methamphetamines  
 Ecstasy  
 Others (specify)  
Hallucinogens 
 
 
 Hallucinogenic mushrooms   
 Ketamine  
 LSD   
 Others (specify)  
Opioids 
 
 
 Heroin   
 Methadone misused (5)  
 Buprenorphine misused (5)  
 Fentanyl illicit/misused (5)  
 Other opioids (specify)  
Hypnotics/sedatives  
 
 
 Barbiturates misused (5)  
 Benzodiazepines misused (5)  
 GHB/GBL  
 Other hypnotics/sedatives misused (5)  
Volatile inhalants/solvents   
New substances imitating the effect of illicit 
drugs such as cannabis, cocaine, etc. 
Specify which substances are imitated  
Anabolic steroids   
Other substances (specify)   
   
Not known   
 
Methodological specifications 
See methodological specifications on drug use from questions B.1.1 and B.1.2. 
                                                          
(5) Without a doctor’s prescription. 
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B.2.3 (Answer this question only if you have used any drug in the last 30 days inside prison during your current 
imprisonment, and have answered YES to question B.2.1.4 for one or more of the listed drugs. Otherwise, go to 
section C.)  
How often have you used drugs in the last 30 days inside prison during your current 
imprisonment? 
Substance groups 
 
 
Specific substances 
 
1. daily 
 
2. 2–6 days per 
week  
3. once a 
week or 
less 
4. not used 
in the last 
30 days 
8. not 
stated/ 
refused 
9. not 
known 
Tobacco        
Alcohol        
Cannabis        
Cocaine 
 
      
 Powder cocaine HCl       
 Crack cocaine       
 Others (specify)       
Stimulants other than cocaine  
 
      
 Amphetamines       
 Methamphetamines       
 Ecstasy       
 Others (specify)       
Hallucinogens 
 
      
 Hallucinogenic mushrooms        
 Ketamine       
 LSD        
 Others (specify)       
Opioids 
 
      
 Heroin        
 Methadone misused (6)       
 Buprenorphine misused (6)       
 Fentanyl illicit/misused (6)       
 Other opioids (specify)       
Hypnotics/sedatives  
 
      
 Barbiturates misused (6)       
 Benzodiazepines misused (6)       
 GHB/GBL       
 Other hypnotics/sedatives 
misused (6) 
      
New substances imitating the 
effect of illicit drugs such as 
cannabis, cocaine, etc. 
Specify which substances 
are imitated 
      
Volatile inhalants/solvents        
Anabolic steroids        
Other substances (specify)        
        
Not known        
 
Methodological specifications 
The question refers to the 30 days prior to the interview, regardless of whether the interviewee has been in prison for less than one 
month.  
See also methodological specifications on drug use from previous questions. 
In cases where the broad category of drugs is used, please specify which sub-categories of drugs are included in the broad 
category. 
                                                          
(6) Without a doctor’s prescription. 
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 (C) Drug injecting and other health risk behaviours 
 
C.1 Have you ever injected any drug (for non-medical purpose), even if just once, outside prison, 
or inside prison during your current imprisonment? 
 C.1.1 
Outside prison 
C.1.2 
Inside prison during the current imprisonment 
 C.1.1.1 
Ever injected 
 
C.1.1.2 
Injected during last 
30 days (7) 
 
C.1.2.1 
Ever injected 
 
C.1.2.2 
Injected during last 30 
days (8) 
 
1. yes 
    
2. no 
    
8 not stated/ 
refused 
    
9. not known 
    
 
Methodological specifications 
If the answer is yes to at least one of the four questions, continue with question C.2. Otherwise, go to section D. 
  
C.2 (Answer this question only if, during your current imprisonment, you have ever injected/currently inject any drug, and have 
answered YES to questions C1.2.1 and/or C.1.2.2. Otherwise, go to section D.)  
During your current imprisonment, if you have injected drugs, have you shared needles/syringes 
or other tools used to inject drugs, even if just once? 
 C.2.1 Needles/syringes C.2.2 Spoon/cooker, filter, cotton, 
acid/lemon juice, rinse water, etc. 
1. yes   
2. no   
8 not stated/refused   
9. not known   
 
Methodological specifications 
The question refers to illicit drug use using an injection during the current imprisonment. 
 
 
 
                                                          
(7) For people who have been in prison for less than one month. 
(8) For people who have been in prison for at least one month. 
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(D) Health status  
D.1 Have you ever had an HIV blood test outside and/or inside prison? 
 D.1.1 Outside 
prison 
D.1.2 Inside 
prison during the 
current 
imprisonment  
D.1.3 Inside 
another prison 
1. never tested    
2. ever tested, results positive    
3. ever tested, results negative    
4. ever tested, results unknown    
8. not stated/refused    
9 not known    
Methodological specifications 
The answer should be based on what is reported by the prisoner and not on tests results. Answers should be provided for all 
settings: outside prison, inside prison during current imprisonment and inside another prison. 
 
D.2 Have you ever had a hepatitis B virus blood test outside and/or inside prison? 
 D.2.1 Outside 
prison 
D.2.2 Inside 
prison during the 
current 
imprisonment 
D.2.3 Inside 
another prison 
1. never tested    
2. ever tested, vaccinated or past hepatitis B     
3. ever tested, active/chronic hepatitis B 
confirmed 
   
4. ever tested, negative (no past hepatitis B, 
not vaccinated, no chronic) 
   
5. ever tested, results unknown    
8. not stated/refused    
9. do not known    
 
Methodological specifications 
The answer should be based on what is reported by the prisoner.  
Answers should be provided for all settings: outside prison, inside prison during current imprisonment and inside another prison. 
When answering the question, please bear in mind the following points, according to the information that is available for the 
prisoner: 
Answer 2. The prisoner is immune against the hepatitis B virus. That means she/he is protected against hepatitis B, and cannot be 
infected or infect others. That can happen if the patient is sufficiently vaccinated (‘positive’ or ‘reactive’ for hepatitis B surface 
antibody — HBsAb = anti-HBs) or if she/he has recovered from a past acute hepatitis B infection (positive HBcAb and positive 
HBsAb). 
Answer 3. The prisoner has been infected by hepatitis B and now she/he has a chronic disease and she/he can infect others. The 
blood test found hepatitis B core antibody (HBcAb) and HBsAg (hepatitis B surface antigen = virus presence). 
4. The prisoner is not immune, so she/he has not protection against hepatitis B, consequently she/he can become infected.  
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D.3 Have you ever had a hepatitis C virus blood test outside and/or inside prison? 
 D.3.1 Outside 
prison 
D.3.2. Inside 
prison during the 
current 
imprisonment 
D.3.3 Inside 
prison during an 
earlier 
imprisonment 
1. never tested    
2. ever tested, results positive    
3. ever tested, results negative    
4. ever tested, results unknown    
8. not stated/refused    
9. do not known    
 
Methodological specifications 
The answer should be based on what is reported by the prisoner. Answers should be provided for all settings: outside and inside 
prison.  
 
D.4 How many times in the last 12 months have you visited a doctor or treatment centre for mental 
or emotional problems? 
 D.4.1 Outside prison D.4.2 Inside prison during the 
current imprisonment 
1. none   
2. once    
3. twice   
4. more than twice   
8. not stated/refused   
9. do not knows   
 
Methodological specifications 
The answer should be based on what is reported by the prisoner. If no service has been visited, go to question D.6. 
 
D.5 (Answer this question if you have visited a doctor and/or a treatment centre for mental and emotional problems, 
and answered 2, 3 or 4 to question D.4. Otherwise, go to question D6.) 
Have you been prescribed any medication for mental or emotional problems in the last 12 
months? 
 D.5.1 Outside prison D.5.2 Inside prison during the 
current imprisonment 
1. yes   
2. no   
8. not stated/refused   
9. not known    
 
Methodological specifications 
The answer should be based on what is reported by the prisoner. 
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D.6 Have you ever had a drug overdose that required professional intervention (by a physician, 
nurse, ambulance)? 
 D.6.1 Outside prison D.6.2 Inside prison during 
the current imprisonment 
1. yes, related to opioids Nº of times /_____/ N° of times /_____/ 
2. yes, related to other drugs 
Specify:_____________________________ 
Nº of times /_____/ Nº of times /_____/ 
3. no   
8. not stated/refused    
9. not known    
 
Methodological specifications 
The answer should be based on what is reported by the prisoner. If no overdose is reported, please go to section E. 
For this study, overdose is defined as ‘an incident occurring shortly after consumption of one or more illicit psychoactive drugs, and 
directly related to this consumption, which was serious enough to require some medical intervention or rescue’.  
Opioids may include heroin, methadone, codeine, morphine, buprenorphine and other prescription opioids. 
 
D.7 (Answer this question only if you have ever overdosed and responded 1 or 2 to question D.6. Otherwise, go to section E.)  
When was your last overdose? 
/_____/ years ago 
/_____/ months ago 
 
D.8 (Answer this question only if you have ever overdosed, and responded 1 or 2 to question D.6. Otherwise, go to section E.) 
Think back to when you last overdosed on drugs. Where were you when you had the first 
symptoms? 
1. inside this or another prison  
2. outside prison  
3. on prison leave 
4. after had been released from a previous imprisonment 
 4.1 /____/ days after prison release 
8. not stated/refused 
9. not known 
 
Methodological specifications 
The answer should be based on what is reported by the prisoner. The question refers to the most recent drug overdose. 
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 (E) Use of health and drug services 
E.1 Have you ever attended or are you currently attending a drug treatment programme? 
 
 E.3.1 Opioid Substitution Treatment 
(e.g. methadone or buprenorphine) 
E.3.2 Drug Treatment other than opioid 
substitution treatment 
Outside 
prison 
Inside prison 
during the 
current 
imprisonment 
 Inside prison 
during previous 
imprisonment(s) 
Outside 
prison 
Inside prison 
during the 
current 
imprisonment 
Inside prison 
during previous 
imprisonment(s) 
1. yes, in the past       
2. yes, currently Not 
applicable 
  Not 
applicable 
  
3. no       
8 not stated/refused       
9. not known       
 
Methodological specifications 
For prisoners who have attended a treatment programme that included both opioid substitution treatment and another drug 
treatment, please answer yes to both types of treatment.  
 
E.2 Do you have access to the following services in this prison, if you wish to use them? 
Type of services Specific 
interventions 
1. 
Always 
2. 
Sometimes 
3. No 
access 
4. Not 
available 
8. Not 
stated/ 
refused 
9. Do not 
know 
Health check-up on prison entry        
Opioid substitution treatment        
Drug treatment other than 
opioid substitution treatment 
Detoxification       
Counselling       
Others (specify)       
Interventions targeting 
infectious diseases  
Screening       
 Hepatitis B vaccination        
 Hepatitis C treatment       
 HIV treatment       
 Others (specify)       
Distribution of sterile material for 
injection 
Sterile syringes/ 
needles 
      
Other sterile material        
Disinfecting tablets/ 
bleach 
      
Overdose prevention        
Free condoms        
Methodological specifications 
‘Overdose prevention’ might include educating drug users about: the risk of polydrug use; the very high risk of overdose in the days 
just after release; other risk factors of overdose; how to prevent drug overdose; how to recognise the signs of and how to manage 
an overdose; naloxone provision, etc. (EMCDDA, 2011). Counselling and low-intensity treatment in prison are described in detail in 
the 2012 EMCDDA Selected issue on drugs and prison (EMCDDA, 2012b). 
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E.3 (Answer this question if you have attended/are currently attending drug treatment, and answered 1 and/or 2 to questions E.1 
and/or E2.)  
Did you start your current drug treatment outside or inside prison? 
 E.3.1 Opioid Substitution 
Treatment 
(e.g. methadone or 
buprenorphine) 
E.3.2 Drug other than Opioid 
Substitution Treatment 
1.initiated in prison   
2. initiated outside prison and continued in prison   
3. initiated outside prison and interrupted in prison   
8. not stated/refused   
9. not known   
Methodological specifications 
The answer should be based on what is reported by the prisoner. 
 
Also consider adding the following questions: unprotected sex; gambling; suicide attempts (add this after the question about seeking 
help in relation to mental health problems); tattoos and/or piercing (outside and inside prison). 
 
(F) Methodological comments 
Indicate any methodological or contextual comments necessary to understand one or more of the 
answers to the questions above. Please refer to the question number and, if necessary, to the specific 
answer concerned. 
Question n._______________________________________________________________________  
Answer n.________________________________________________________________________ 
Question n._______________________________________________________________________  
Answer n.________________________________________________________________________ 
Question n._______________________________________________________________________  
Answer n.________________________________________________________________________  
Question n._______________________________________________________________________  
Answer n.________________________________________________________________________ 
Question n._______________________________________________________________________  
Answer n.________________________________________________________________________ 
Question n._______________________________________________________________________  
Answer n.________________________________________________________________________ 
Question n._______________________________________________________________________  
Answer n.________________________________________________________________________ 
Question n._______________________________________________________________________  
Answer n.________________________________________________________________________  
Question n._______________________________________________________________________  
Answer n.________________________________________________________________________  
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Introduction 
 
Conducting surveys in a prison setting is a difficult task. The specific environment where the survey is 
conducted and the profile of the potential interviewees pose drawbacks in the development of the 
fieldwork and limit the methodological aspects of the study.  
 
Some methodological aspects are described below as principles and recommendations to be followed 
when conducting a survey in prison. Their objective is to guarantee a high level of quality when 
conducting the research and to increase the comparability of the data across countries in the research 
management. Another objective is to ensure high ethical standards are maintained in the studies, due 
to the special conditions of the target population. 
 
A range of European Monitoring Centre for Drugs and Drug Addition (EMCDDA) and international 
(United Nations and World Health Organization) tools have been used as methodological and 
theoretical reference to draft these guidelines, including: the Handbook for surveys on drug use 
among the general population (EMCDDA, 2002), the Treatment demand indicator (TDI): standard 
protocol 3.0 (EMCDDA, 2012a) and the ‘Drug Related Infectious Diseases (DRID) Guidance module’ 
(http://www.emcdda.europa.eu/themes/key-indicators/drid). United Nations (UN) and World Health 
Organization (WHO) guidelines on drugs and prison were also taken into consideration (WHO, 2005, 
2009, 2010).  
 
 
Principles 
 
Some general principles should be considered when establishing and implementing a survey on drugs 
and prison; those principles should be common at the European level, as agreed in the 
methodological framework for monitoring drugs and prison in Europe (Council of the European Union, 
2013). 
  
Aim 
The information on drugs and prison is to be collected from a public health perspective, and should 
not focus on the principle of control. The public health perspective should be the driving force for 
gathering any type of information in the context of the survey on drugs and prison. The aim is to 
collect information that can be used to improve health, social services and facilities for prisoners and 
ultimately improve the physical, psychological and social conditions of prisoners; this should improve 
the health of the whole community.  
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Survey management 
The institutions and state administrations responsible for health at the national level (usually the 
Ministry of Health) should be involved in the management of the research, if possible taking the lead 
on the survey’s organisation and on the assignment of tasks; the same institution should also be in 
charge of the survey’s funding and coordinate the analysis and the use of the results. The judicial and 
penitentiary administration system should support the survey’s implementation and the fieldwork. 
Incentives for participating in the study may be used in the same way as when conducting surveys in 
the general population. The survey should be carried out by institutions that are independent of the 
prison setting and known for their high scientific and professional standards (Council of Europe, 
2006). 
 
Existing tools 
When establishing a survey that will be implemented in a prison setting, it is advisable to consider 
existing tools rather than to develop new tools, if possible, in order to harmonise with the European 
guidelines and thereby obtain added value both at the national and European level. It is also advisable 
to adapt existing national tools and harmonise them with the European guidelines, to increase their 
added value. If tools for data collection do not exist at the national or local level, they should be built 
considering the European guidelines.  
 
Minimum core data-set 
The proposed questionnaire is a European minimum core data-set that should be common for all 
European countries, to ensure harmonisation and comparison. Countries can expand their own survey 
with additional items to cover national or local information needs. 
 
Methodological guidelines 
The questionnaire is complemented by these methodological guidelines for data collection and 
reporting. The methodological guidelines aim to guarantee high quality in the collected information 
and comparability between countries, and to ensure that high ethical standards are applied. Additional 
national guidelines and/or more extensive instructions and rules for implementing the survey and 
fieldwork manuals can be produced, according to national or local needs and requirements. 
 
Questionnaire/data collection form 
The tool published with the current methodological guidelines is a European Questionnaire on Drug 
use among Prisoners (EQDP). Countries are invited to use the questionnaire in prison to collect 
information on drug use among prisoners. The objective of having a common questionnaire is to 
obtain the same information in every country; the information that is collected will be based on 
harmonised definitions, and the way the questions are formulated and the guidelines to implement 
them should be the same. Nevertheless, every country can adapt the questionnaire to its national 
language. As indicated above, additional items can be included for national or local purposes.  
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Triangulation of sources 
The data collected through surveys in prisons have several limitations related to the specificity of the 
setting and the sensitive nature of the subject being studied (drugs). It is therefore important to 
triangulate the survey’s results with other information sources, which may come from other studies, 
routine data collection and other unofficial information sources (Carpentier et al., 2012).  
 
Terminology 
Particular attention should be paid to terminology, both in the questionnaire and in the methodological 
guidelines adapted to the national context. The language used in the questionnaire should consider 
the specificity of the prison’s environment. The language should be understandable and adapted to 
the cultural and educational level of the prisoners, and should be written in their spoken language 
(which might differ from the official language of the country where the prisons are located). In some 
countries the majority of prisoners are foreigners, and the questionnaire may need to be translated 
and/or interpreted. Particular attention should also be paid to the translation from English to national 
languages, in order to retain the exact meaning of the formulation proposed in the European 
questionnaire and ensure the harmonisation of the data.  
 
Ethical issues  
Collecting data in prison settings is a sensitive issue, and ethical principles should be carefully 
considered at every phase of the survey. High ethical standards should be set before the survey starts 
and maintained during its implementation. The survey should be carried out in a way that promotes its 
potential benefits for the prisoners. The prisoners should be informed about the aim of the survey, 
they should provide verbal and written consent for their participation and they should be informed 
about how it will be managed and how its results will be used. The survey should not be used to 
attempt to change the prisoner’s drug use patterns, or to influence them in any way — the only goal of 
the survey must be to collect information for monitoring, statistical and research purposes. This should 
be made clear to prisoners and to the prison administration before the study starts.  
 
International rules of confidentiality and data protection, and guidelines for respecting prisoners’ rights, 
including human rights, must be followed. In particular, the following two international guidelines 
should be considered to be reference points when implementing the survey: (1) the UN publication 
Human rights and prisons: a pocketbook of international human rights standards for prison officials 
(United Nations, 2005); and (2) the WHO guide Health in prisons: a WHO guide to the essentials in 
prison health (WHO, 2007). These guidelines should be read and taken into consideration when 
implementing research and surveys in prison settings. Furthermore, principles for conducting medical 
research in a way that respects the health of the survey participants should be followed (Council of 
Europe Committee of Ministers, 1993). All people and institutions involved should be informed and be 
aware of these principles and rules, including the interviewers, the prison staff, the prisoners and all 
subjects involved in the survey (United Nations, 1990, 2005; WHO, 2007). 
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Guidelines 
 
Survey aims 
It is important to specify the objective of a survey in order that the data to be collected can be 
identified, and the methods and tools for data collection established. The aim of this survey is to 
increase the knowledge on drug use among prisoners, their health status and related consequences, 
and to better identify the health, psychological and social need of the prisoners. This information can 
facilitate the development of appropriate public health and social services (treatment, prevention, 
harm reduction, etc.). The survey should also ultimately make those services more accessible for 
prisoners or former prisoners, both inside prison and at an early stage after prison release. 
 
Method of the survey  
The method used to administer the European Questionnaire on Drug use among Prisoners should be 
based on a cross-sectional survey among prisoners on their drug use, patterns of drug use inside 
and outside prison, health problems that may be related to drug use and their use of drug and health 
services. A long process of analysis and assessment preceded the decision to define a common 
European Questionnaire on Drug use among Prisoners. In particular, data collected over the previous 
10 years on drug use among prisoners in Europe were assessed and analysed, showing the need for 
harmonisation and indicating the definition of a common European questionnaire as a possible tool for 
data collection. In addition, during the last period (Carpentier et al., 2012) a specific assessment of 
information and methodologies was conducted, collecting and assessing the structure of, and the 
information from, 45 questionnaires and data collection forms on drug use among prisoners that had 
been used to conduct surveys in prisons in 23 European countries (Royuela et al., 2013). 
 
Periodicity of the survey 
It is recommended that the proposed questionnaire is administered every two years, as in the case of 
the general population survey. Following the recommendations used in the assessment of the 
implementation of the key indicator general population surveys, it is recommended that the maximum 
time interval between two surveys should be four years ( EMCDDA, 2002). It is recommended that the 
first survey should start 2016, in order to harmonise the reference years in all countries, and to 
harmonise future survey dates. It would also be preferable if the survey were conducted in the same 
period of the year in all countries, possibly between April and May. However, some flexibility is 
allowable because of differences in countries’ organisation and the national resources that are 
available. 
 
Target population 
The target population of the survey should include all prisoners in a given day/week in all custodial 
institutions. The categories of prisoners included are those specified in SPACE 1: Council of Europe 
annual penal statistics (Aebi and Del Grande, 2011).  
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The prisoners are divided into the following categories according to their legal status and their place of 
imprisonment: 
 
a) Prisoners by legal status  
• Untried detainee (no court decision yet reached). 
• Sentenced prisoner who has appealed or who is within the statutory limits for doing so. 
• Detainees who have not yet received a final sentence but have started serving their custodial 
sentence in advance. 
• Sentenced prisoners (final sentence). 
b) Prisoners by place of imprisonment  
• Persons held in penal institutions designed for serving a custodial sentence. 
• Persons held in remand institutions (generally designed for pre-trial detainees and for those 
serving short-term custodial sentences). 
• Persons held in custodial and/or educational institutions/units for juvenile offenders. 
• Persons held in police stations (if these stations are under the authority of prison 
administration and if the persons held have the status of ‘inmates’). 
• Persons held in institutions for drug‐addicted offenders outside penal institutions (if the 
persons have the status of ‘regular inmate’). 
• Persons with psychiatric disorders who are held in psychiatric institutions or hospitals outside 
penal institutions (if the persons have the status of ‘regular inmate’). 
 
These groups may vary by country, as not all categories apply to every country. Countries should 
specify what the situation is regarding the prisoners’ grouping at the national level. It will be necessary 
to specify which groups have been included and excluded in the survey as it is possible that, for 
practical reasons, some groups will not be included (e.g. people in psychiatric institutions). 
 
Access to prison  
It is important to establish or reinforce connections with prison institutions and in particular with the 
Ministry of Justice, which usually has access to the prisons’ databases of inmates. Specific 
agreements should be established with the relevant authorities. The conditions to access the prison 
should be set up and agreed in a specific regulation between the institution responsible for the survey 
and the local authorities (e.g. prison directors).  
 
If juveniles are participating in the survey (even if they are in custody) then special permits should be 
obtained from parents or legal guardians. This condition will also apply to anyone under legal 
guardianship, which might occur relatively often for people with a long history of drug use. 
 
Sampling 
The sampling method will depend on the objectives of the study. In the case of general population 
studies, the assessment of population estimates from sample data requires representative samples of 
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the total population. In the case of prison, the sample should be representative of the entire prison 
population (EMCDDA, 2002) and should be drawn randomly using the population registered as being 
in prison in a given day/week. Ideally a multi-stage sampling (i.e. a type of clustering sampling) should 
be followed; this type of sampling anticipates several levels of cluster selection that may be applied 
before the final sample elements are reached. The survey will then focus on specific chosen clusters. 
In order to guarantee sufficient information on groups of prisoners with particular health and social 
needs, these groups should be over-represented in the sample. They may include women prisoners, 
juvenile detainees, young adult offenders, foreigners or others and these groups may vary between 
countries. It is advisable that the sampling is done (or supervised) by the research institution 
conducting the survey, rather than by the prison service administration, to avoid possible biases. 
 
Introduction to the interview 
Before the fieldwork begins the prisoners must be briefed about the general and specific objectives of 
the survey, including how it will be organised and how the final results will be used. It is very important 
to inform each participant about the benefits of the survey, the rights of participants and how 
anonymity and confidentiality will be handled. It is also necessary to explain how the results of the 
study will be used, particularly regarding public health benefits. This predominantly refers to the fact 
that the information obtained from the survey will be used to assist stakeholders to develop public 
health programmes that target efforts to lower the risk factors that are related and lead to drug use 
and problems (e.g. infectious diseases, overdoses). The introduction to the interview can be done by 
talking to prisoners, or via letters and leaflets. It is important to ensure that the prisoners are informed 
about and aware of the survey and their participation in the study. An introduction to the survey should 
also be provided to prison staff and management, including prison administration (director, etc.). 
 
Individual rights of the participants in the study 
Prisoners selected to participate in the study may decline to take part, withdraw their consent at any 
time or choose not to any question in the survey. 
 
Anonymity and confidentiality 
Participation in the survey and the data it provides must be strictly confidential. The respondent must 
be assured that her/his responses will remain confidential. It is not enough to simply state this; it 
should also be obvious from the setting of the interview and the traceable procedures for handling the 
completed questionnaires. It should be made clear to the participants that while the data from the 
study may be sent elsewhere for analysis, no personally identifiable information will be provided for 
this analysis. Prisoners’ names will not appear in any output document of the study. The confidentiality 
of all participants is guaranteed, and inmates’ names should not be written on the questionnaire. Each 
participant must provide both verbal and written consent before taking part in the survey. Every 
country and institution responsible for the survey is free to make its own decision on the best way to 
guarantee interviewees’ anonymity. 
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Non-response 
If the selected inmate declines to take part in the study, her/his refusal should be accepted. Some 
information on non-response could be applied in order to model non-response and treat it in the data 
management phase. However, attention should be paid to maintaining anonymity and confidentiality in 
the management of non-responses. 
  
Interview methods  
The method of data collection is a crucial decision when designing a survey. This is also valid for 
surveys in prison settings. Each interviewing approach has advantages and disadvantages and may 
have drawbacks and generate biases affecting the response rates and the reliability of the answers 
that are obtained. The type of method chosen therefore has implications for the quality and quantity of 
the survey results. 
 
Three possible categories of interviewing could be applied in prison settings: 
1. Computer-assisted personal interviewing (CAPI). 
2. Face-to-face interview. 
3. Self-administered questionnaire. 
 
There is no obligation to choose one of these methods; it is up to the country and the research 
institution to decide on the most suitable method to be used in their survey. Sometimes, a mix of 
methods may be appropriate, as in the case of sensitive questions that might be better answered 
without the intervention of an external interviewer. That decision should be taken by those responsible 
for the survey. This mixed approach may cause limitations in data comparability, but it may also enrich 
the validity of some answers. It is, however, extremely important to describe in detail the method used 
for the whole questionnaire or parts of it. A short description of each method is provided below, in 
order of preference, although the actual method used will depend on practical constraints (budget, 
premises, etc.). 
 
1) Computer-Assisted Personal-Interviewing (CAPI)  
CAPI ensures confidentiality, autonomy and a safe setting for responding to the questions. The 
interviewee is given a computer/tablet and is asked to self-complete the interview without assistance 
of anyone, although she/he can ask the interviewer questions if clarification is needed 
(http://srmo.sagepub.com/view/encyclopedia-of-survey-research-methods/n82.xml). 
 
CAPI is user-friendly and provides an efficient way to manage the data. However, some preconditions 
must be established with the prisons before it is used — they should allow the use of electronic 
devices, such as laptops, tablets, smartphones, etc., that are password protected and contain 
encrypted surveys. The development of user-friendly interfaces has proceeded rapidly, with 
techniques such as touch screens, colour graphic images, sound and recordings of respondents and 
answers to open-ended questions now available. These are increasingly user-friendly technologies, 
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so respondents do not need to be experienced computer users. Training should be provided to people 
in charge of implementing the survey.  
Advantages  
This method has the advantage of being able to incorporate automatic consistency checks. 
Interviewers can be alerted to any inconsistencies within the data and resolve them with the 
interviewee during the process. The data are controlled for double counting and are correctly coded, 
and missing values are assigned for all items. The interview can be administered in a short period of 
time. The role of the interviewer is strictly controlled, yielding higher-quality data. Data are recorded, 
exported and integrated in a database, and managed rapidly and economically.  
Disadvantages  
Despite these advantages, debate still continues about what effects this method might have on survey 
outcomes compared to modes such as face-to-face interviews. Questions can be misinterpreted or 
misunderstood, for instance, as in the case of the self-administered questionnaire, and doubts about 
confidentiality and fear of external and remote controls on the survey information have also been 
raised in this specific environment. 
 
2) Face-to-face interview 
The face-to-face interview is carried out on the prison premises by trained interviewers. The 
interviewers should be instructed on several topics related to survey methods and the prison 
environment. These include interview skills, the method of conducting an interview, how best to 
approach prison organisations, making appointments for briefing prisoners and carrying out 
interviews, keeping track of interviews and non-responses, informing prisoners and obtaining consent, 
and giving feedback to prisoners.  
The face-to-face interview is based on a personal encounter between interviewer and respondent. 
The interviews are structured by means of a standardised questionnaire. The interviewer asks the 
questions and fills in the pre-coded answers. When sensitive issues are involved, the interviewee may 
complete parts of the questionnaire and hand it to the interviewer in a closed envelope, or post it back 
later.  
Advantages  
This method has the advantage of ensuring the accuracy of the answers and the high level of 
information given to the respondents on the survey’s aim and the exact meaning of the questions. 
Also, questions that might be difficult to understand for some prisoners can be easily explained in a 
face-to-face interview. 
Disadvantages  
This method has the disadvantage of being more expensive than the other methods. It is likely to have 
higher fake responses or non-response for sensitive questions. It is more time consuming than the 
other methods. 
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3) Self-administered questionnaire 
This method can be applied using standard pen-and-paper questionnaires. The questionnaire is 
distributed to the inmates by people who are considered the ‘contact person’ in the prisons. The 
contact people should have the ability to guarantee information anonymity and confidentiality — staff 
who are already working in institutions (health services, universities, research institutes, etc.) and are 
independent from the prison services would be the preferred choice. After the questionnaire has been 
completed, forms should be placed in envelopes that are collected by the contact persons in each 
prison. The responses are subsequently compiled by scanning the survey forms or by manually 
entering them into a database before analysis.  
Advantages  
This method only requires a simple and low-cost infrastructure. The prisoner’s confidentiality is also 
guaranteed.  
Disadvantages 
The disadvantage may be related to the accuracy of the answers and the likely high rate of 
missing/empty answers. Also, the researcher cannot control for double counting, since a person may 
fill in more than one questionnaire. The data management phase would also be more complex and 
time consuming. 
 
Data management 
Data management is an important phase of the survey and should be planned in advance, in detail 
and for every phase before the survey starts. It is necessary to plan what format the data should have 
after the data collection, who should enter the data and how, which software should be used for 
collecting and analysing the data, etc. Some of these considerations will depend on the method 
chosen for the survey; for instance, the data may be scanned or entered manually in the case of face-
to-face interviews, but are automatically entered into a database if computer-assisted self- interviews 
are used. Manuals for conducting social research may be consulted for more detailed information on 
how to handle the data management in a survey. 
 
Missing values 
Respondents do not always answer questions in the way the survey designer expects. This can be 
because the respondents may not want to answer particular questions, may not understand a 
question, may skip a question accidentally or may assume that the question does not apply to them, 
even if in fact it should be answered. As a result, survey data will include missing values or 
inconsistent values. The number of missing values and inconsistencies can be reduced by choosing 
an appropriate mode and questionnaire design, but they cannot always be avoided. This is particularly 
true for self-administered questionnaires (standard pen-and-paper questionnaires), where an 
interviewer cannot intervene. A computer program guiding the respondent through the questionnaire 
thus can help to prevent respondents skipping questions by guiding them through the survey, and can 
draw attention to inconsistencies with previous answers.  
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There are no uniform solutions for handling these problems. The threshold for missing data should be 
flexible depending on the characteristics of the structure of the data-set. Specific incomplete records 
having more than three-quarters of the questions empty should be consider as a potential source of 
bias. By dropping these records the percentage of missing data in specific items will decrease. Also, 
items with missing values higher than a quarter of the sample could bias the analysis. There are 
several ways to deal with these items; some researchers will carry out analysis to investigate missing 
data imbalance in all relevant items and whether respondents with and without missing values have 
different characteristics. Applying methods for imputation of missing data is another possible solution, 
or the records may be dropped from the analysis, though this is not recommended, as deleting the 
whole record will reduce the response rate. Whichever approach is chosen for handling missing 
values, the method should be documented, both when corrections are made to the original data and 
when cases are deleted from the original data file. 
 
Data documentation requirements 
The overall procedures used in the implementation of the survey and subsequent data management 
need to be clearly documented by the institutions leading and conducting the survey in prisons. 
Ideally, this should be represented as part of a full technical report that describes the problems 
encountered during the implementation of the survey, the way in which these problems have been 
solved and a full account of the responses.  
 
Data quality 
Data quality is extremely relevant for drug-related data in prison. Attention to data quality is even more 
important when it applies to a European data-set, where information should be comparable across 
countries and consistent over time in all countries. Control of data quality should be applied in every 
phase of the survey, from data collection to data analysis. Basic validation procedures should be 
implemented on data completeness, consistency and timeliness, and outliers should be identified from 
the general prison picture, from past surveys, and from surveys in prisons other than the prison 
currently involved in the survey. Particularly interesting for the European data-set is the identification 
of outliers between countries, which might indicate real differences between them, or a lack of 
comparability at the methodological level. Methodological information should be reported and 
described in detail and accurately in the phases of data collection, entering, reporting and analysis.  
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